Questions About Cancer? 1-800-4-CANCER

Breast Cancer Prevention (PDQ®)

Health Professional Version
Last Modified: 04/04/2014

Changes to This Summary (04/04/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of Evidence

Added text about the International Breast Cancer Intervention Study II that randomly assigned 3,864 postmenopausal women who were at increased risk of developing breast cancer to receive either daily anastrazole or placebo for 5 years; after a median follow-up of 5 years, fewer breast cancers occurred in the anastrazole treated group than in the placebo group (cited Cuzick et al. as reference 108).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.